Browse the latest research summaries in the field of immunology for spinal cord injury patients and caregivers.
Showing 611-620 of 730 results
Cell Mol Neurobiol, 2015 • April 4, 2015
The study aimed to determine the effects of BDNF on inflammatory responses, focusing on macrophage polarization, after spinal cord injury (SCI) in mice. Results showed that BDNF promotes the shift of ...
KEY FINDING: Lenti-BDNF injections increased BDNF levels and promoted M2 macrophage polarization at the injury site.
Journal of Neuroinflammation, 2015 • June 11, 2015
This study demonstrates that DRα1-mMOG-35-55, a novel construct, can effectively treat EAE in MHC-mismatched mice by reducing CNS inflammation. The treatment's efficacy is potentially mediated by an i...
KEY FINDING: DRα1-mMOG-35-55 effectively treats EAE in MHC-mismatched C57BL/6 mice by reducing CNS inflammation.
Stem Cell Research & Therapy, 2015 • September 3, 2015
This study compared the effects of adult bone marrow-derived mesenchymal stem cells (MSCs) and neural crest stem cells (NCSCs) in a mouse model of spinal cord injury (SCI). Both cell types were found ...
KEY FINDING: Both MSCs and NCSCs induced motor recovery in mice with spinal cord injury.
Scientific Reports, 2015 • November 9, 2015
This study demonstrates that human AT-MSCs can exert neuroprotective and immunomodulatory effects in a rat model of ventral root avulsion (VRA). The researchers found that human AT-MSCs locally suppre...
KEY FINDING: AT-MSCs transplantation increased neuronal survival and partially preserved synaptophysin-positive nerve terminals.
Journal of Neuroinflammation, 2015 • November 18, 2015
AZM treatment increases macrophage expression of anti-inflammatory genes and facilitates significant improvements in SCI locomotor recovery and tissue sparing. Macrophages, purified from the injured s...
KEY FINDING: SCI mice exhibited significantly increased anti-inflammatory and decreased pro-inflammatory macrophage activation in response to AZM treatment.
Stem Cell Research & Therapy, 2015 • November 9, 2015
The study introduces a robust potency assay using inhibition of pooled polyclonal T-lymphocyte proliferation after mitogen or antibody stimulation and due to allo-antigen-driven mixed leukocyte reacti...
KEY FINDING: Significant potency inconsistency and diminished allo-immunosuppression in MSPCs compared to dose-dependent inhibition of mitogenesis.
PNAS, 2015 • December 29, 2015
This study investigates the use of MHC-mismatched mixed chimerism to treat experimental autoimmune encephalomyelitis (EAE) in mice, an animal model for multiple sclerosis (MS). The findings demonstrat...
KEY FINDING: MHC-mismatched mixed chimerism eliminates clinical symptoms and prevents relapse of EAE in mice.
Current Neuropharmacology, 2016 • January 21, 2016
Alzheimer’s disease, Parkinson’s disease, traumatic brain and spinal cord injuries and multiple sclerosis, are classically categorized as rather different diseases of the CNS, recent data indicate tha...
KEY FINDING: MSCs of dental origin have multiple differentiation potential towards osteogenic and odontodenic directions as well as neurogenic, adipogenic and chondrogenic lineages.
Brain, 2016 • January 29, 2016
Aging in the central nervous system (CNS) leads to a loss of gray and white matter, contributing to cognitive decline, which is further exacerbated by neurological disorders. This is accompanied by an...
KEY FINDING: Macrophages and microglia, two types of immune cells in the brain, age in distinct ways, with macrophages showing diminished pro-inflammatory responses and microglia exhibiting an exaggerated pro-inflammatory response with age.
Journal of Neuroinflammation, 2016 • April 28, 2016
This study investigated the effect of IL-25 on functional recovery in a mouse model of SCI, exploring both local and systemic administration methods. The results showed that systemic IL-25 administrat...
KEY FINDING: Systemic administration of IL-25 did not influence functional recovery following SCI in mice.